Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845166 · ClinicalTrials.gov registry record · Phase 1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
A Phase 1 study of Colorectal Cancer and Renal Cell Carcinoma, sponsored by Exelixis.
- Active
- Registry status
- Phase 1
- Development phase
- 325
- Enrollment target
- 20
- Study locations
NCT03845166 is a Phase 1 study of Colorectal Cancer and Renal Cell Carcinoma that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 325 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03845166, a Phase 1 study of Colorectal Cancer and Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 325 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG XL092
- DRUG Avelumab
Study Locations (20)
California
- Exelixis Clinical Site #6 - Duarte
- Exelixis Clinical Site #49 - La Jolla
- Exelixis Clinical Site #7 - Los Angeles
- Exelixis Clinical Site #84 - Los Angeles
- Exelixis Clinical Site #66 - San Francisco
- Exelixis Clinical Site #71 - Stanford
Florida
- Exelixis Clinical Site #15 - Lake Mary
- Exelixis Clinical Site #24 - Miami
Georgia
- Exelixis Clinical Site #11 - Atlanta
- Exelixis Clinical Site #80 - Atlanta
Michigan
- Exelixis Clinical Site #45 - Ann Arbor
- Exelixis Clinical Site #2 - Grand Rapids
Iowa
- Exelixis Clinical Site #41 - Iowa City
Kansas
- Exelixis Clinical Site #36 - Westwood
Maine
- Exelixis Clinical Site #62 - Scarborough
Maryland
- Exelixis Clinical Site #44 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845166
The ClinicalTrials.gov registry entry for NCT03845166 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03845166 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03845166 about?
NCT03845166 is a clinical study titled "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors". This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with ad...
What is the current status of trial NCT03845166?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 325 participants. The study started on 2019-03-20. Estimated completion is 2027-05-31.
What conditions does trial NCT03845166 study?
This clinical trial studies the following conditions: Colorectal Cancer, Renal Cell Carcinoma, Metastatic Castration-Resistant Prostate Cancer, Hormone Receptor-Positive Breast Carcinoma, Neoplasm Malignant.
What interventions are being tested in trial NCT03845166?
The interventions under investigation include: Atezolizumab (DRUG), XL092 (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03845166?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845166 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.